SCHEMBL5872311

SCHEMBL5872311

CCOC1(C2CCN(CCc3ccc(F)cc3)CC2)CCCc2cc(O)ccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 3/20 0.42
ESR2 Q92731 2/20 0.42
HTR2A P28223 5/20 0.41
HTR2C P28335 3/20 0.41
HTR7 P34969 2/20 0.41
ADRA1B P35368 2/20 0.40
ADRA1D P25100 1/20 0.40
ADRA1A P35348 1/20 0.40
PABPC1 P11940 1/20 0.40
HTR6 P50406 1/20 0.39
OPRM1 P35372 3/20 0.39
TMEM97 Q5BJF2 3/20 0.39
OPRK1 P41145 2/20 0.39
OPRD1 P41143 1/20 0.39
DRD2 P14416 1/20 0.38
ADRA2B P18089 1/20 0.38
DRD1 P21728 1/20 0.38
HRH1 P35367 1/20 0.38
HTR2B P41595 1/20 0.38
KCNQ1 P51787 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5871114 0.70 HTR2A (0.46) ESR1ESR2HTR2AHTR2CHTR7
SCHEMBL5871307 0.68 HTR1A (0.47) HTR2AHTR2CHTR7HTR6
SCHEMBL7529927 0.66 SIGMAR1 (0.51) HTR2AHTR2CHTR7HTR6HTR2B
SCHEMBL17778866 0.66 SIGMAR1 (0.50) HTR2AHTR2COPRM1OPRK1OPRD1
SCHEMBL4232561 0.63 HTR2A (0.64) HTR2AHTR2CHTR7HTR6OPRM1
SCHEMBL1457116 0.63 HTR2A (0.64) HTR2AHTR2CHTR7HTR6
SCHEMBL14708456 0.63 HRH3 (0.75) HTR2AHTR2CHTR7ADRA1AHTR6
SCHEMBL5872098 0.63 DRD2 (0.43) HTR2AHTR2CHTR7HTR6OPRM1
SCHEMBL5871302 0.63 DRD2 (0.43) HTR2AHTR2CHTR7HTR6OPRM1
SCHEMBL27541561 0.62 HTR2A (0.63) HTR2AHTR2CHTR7HTR6OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7071201-B2 Serotonin antagonism; muscle relaxant for myotonia; such as 1-(1-(2-(4-methoxyphenyl)ethyl)piperidin-4-yl)-7-methoxy-1,2,3,4 -tetrahydroquinoline EISAI CO., LTD. (JP) 2006-07-04 US disclosed
US-6448243-B1 SEROTONIN ANTAGONIST FOR TREATING, AMELIORATING AND PREVENTING SPASTIC PARALYSIS OR CENTRAL MUSCLE RELAXANTS FOR AMELIORATING MYOTONIA EISAI CO., LTD. (JP) 2002-09-10 US disclosed
US-20020086999-A1 Certain quinoline derivatives EISAI CO., LTD. 2002-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020086999-A1 Certain quinoline derivatives CHRM1, CHRNA5, CHRNA4 ESR1 4837/4885ESR2 4379/4885HTR2A 143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.